Close
Help




JOURNAL

Clinical Medicine Insights: Oncology

1,064,169 Journal Article Views | Journal Analytics

Nelarabine in the Treatment of Refractory T-Cell Malignancies

Submit a Paper



Publication Date: 01 Dec 2010

Type: Review

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2010:4 133-141

doi: 10.4137/CMO.S4364

Abstract

Nelarabine is a nucleoside analog indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that is refractory or has relapsed after treatment with at least two chemotherapy regimens. After being first synthesized in the late 1970s and receiving FDA approval in 2005, the appropriate use of nelarabine for refractory hematologic malignancies is still being elucidated. Nelarabine is the prodrug of 9--D-arabinofuranosylguanine (ara-G) which when phosphorylated intracellularly to ara-G triphosphate (ara-GTP), preferentially accumulates in cancerous T-cells. Dose-dependent toxicities, including neurotoxicity and myelosuppression, have been documented and may, in turn, limit the ability to appropriately treat the diagnosed malignancy. This article will summarize the pharmacologic properties of nelarabine and will address the current place in therapy nelarabine holds based upon the results of the available clinical trials to date.



Downloads

PDF  (532.72 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Oncology
Our experience publishing in Clinical Medicine Insights: Oncology was the easiest and most user-friendly interface we have encountered.  The staff were very attentive to us and kept us posted at every step of the process.  It was rewarding to have our article appear in press within weeks, compared to months at other journals.
Dr Darrell Ellsworth (Windber Research Institute, Windber, PA, USA)
More Testimonials

Quick Links


Follow Us We make it easy to find new research papers.